Login / Signup

Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.

Huaqi LiScott HuntingtonCary GrossShi-Yi Wang
Published in: PloS one (2024)
Patients with AD were less likely to receive immunotherapy as first-line and overall therapy for treatment of their advanced cancer. However, among those who did receive at least one cycle of immunotherapy, patients with AD received a similar number of cycles compared to patients without AD. This not only indicates that AD is not an absolute contraindication for immunotherapy in clinical practice but may also demonstrate overall treatment tolerability and net benefit in patients with AD.
Keyphrases